ATIP is a focused funding program designed to start or facilitate new, translationally oriented research projects by clinical and non-clinical faculty at Johns Hopkins University.

Article courtesy of Emily Myrick/ The HUB Since its inception in 2015, the interdisciplinary project through the Institute for Clinical and Translational Research has prompted meaningful changes in hospital protocol Last month, 16 teams of Johns Hopkins engineering students presented doctors, nurses, and administrative staff at Johns Hopkins Hospital with recommendations, written reports, and prototypes designed to improve the safety and efficiency of hospital care, the conclusion of an eight-week project facilitated by the Institute for Clinical and Translational Research. This consulting project, which the Master of Science in Engineering Management program informally calls the “hospital project,” is part of Strategies for Innovation … Continue reading →

  Article courtesy of Johns Hopkins Technology Ventures   Barbara Slusher, Ph.D., M.A.S., director of Johns Hopkins Drug Discovery, and co-leader of the ICTR Drug, Biologics, Vaccines and Devices Translational Research Community recently sold to Bayer AG her startup that developed a shielding agent for a patient’s normal tissue that can be used during a cutting edge, targeted radiotherapeutic treatment for prostate cancer. “To me,” she says, “the science story here is the value of keeping your eyes open, because if you do, failures can turn into successes.” That’s because Slusher is not a prostate cancer expert — she is a … Continue reading →

View Course Flyer October 25- December 10 The course — MEDI 502: Translational Science in the COVID-19 Pandemic – Accelerating and Enhancing our Response Across Preclinical, Clinical, and Population Health Research — is offered by NCATS in partnership with the Foundation for Advanced Education in the Sciences (FAES), which is located at the NIH. The course describes in detail a range of recent and ongoing research activities — from preclinical to clinical to population health — that were led or supported by NCATS in response to the COVID-19 pandemic. Through this lens, the course teaches students effective approaches and strategies in translational … Continue reading →

New Data Protection Attestation streamlines paperwork associated with sharing limited data sets for research among JHU researchers.   The Data Protection Attestation available here outlines expectations for the protection of patient data and serves as a data use agreement to enable the sharing of limited data sets among JHU researchers, (both those in and outside of the JHM covered entity).   As of 8/26/2021, when study team members “agree to participate” for any study in eIRB and when a PI submits a new application or further study action, researchers agree to the terms of the Data Protection Attestation.   This … Continue reading →

Mark Sulkowski, MD, Director of the COVID-19 Clinical Research Center named senior associate dean for clinical trials and the founding director of the Office of Clinical Trials at the Johns Hopkins University School of Medicine.   In his new role, Dr. Sulkowski will oversee activities related to clinical trials, focusing on commercial clinical trials. In addition, he will help develop an integrated approach to trial-related training, support and oversight. He will join the team of Gail Daumit, the new vice dean for clinical investigation, and with her will collaborate closely with Daniel Ford, director of the Institute for Clinical and … Continue reading →

Open to all Johns Hopkins University Full-Time Faculty Members with an appointment of 5 years or fewer.   The Clinical Research Scholars Program (KL2) is accepting applications for the 2022 KL2 Mentored Career Development Awards. KL2 supports the career development of faculty members dedicated toward a career in clinical investigation. This is a three year program with support provided for two years by the KL2 and one year by the nominating division/department. The application deadline is Wednesday, December 1, 2021 by 11:59 pm. Awards consist of: Up to $110,000 in annual salary support (plus fringe) for 2 years. Up to … Continue reading →

Cancer-fighting T cells from patients whose cancers responded to immunotherapy and from those whose tumors did not respond showed marked differences A tumor-specific T cell engages with a tumor cell. Bystander T cells do not engage with the tumor. Credit: PNAS Dec. 10, 2002, Copyright (2002) National Academy of Sciences, U.S.A.   Cancer-fighting immune cells in patients with lung cancer whose tumors do not respond to immunotherapies appear to be running on a different “program” that makes them less effective than immune cells in patients whose cancers respond to these immune treatments, suggests a new study led by researchers at … Continue reading →